EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours

Marie Robert, Nuria Kotecki, Carlos Gomez-Roca, Christophe Massard, Sophie Postel-Vinay, Judith Raimbourg, Mariana Brandao, Iphigénie Korakis, Thibaut de la Motte Rouge, Silvia Comis, Karima Imadalou, Caroline Chevalier und 12 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116729 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Marie Robert und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, MonoclonalHumansFemaleAgedMiddle AgedMaleAdultAged, 80 and overAdolescentYoung AdultChild, PreschoolMaximum Tolerated DoseDose-Response Relationship, Drug

Stichwörter der Autor:innen

Immune checkpoint inhibitorOSE-279PD-1Phase ISolid tumours

Substanzen

Antibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Institut de Cancérologie de l'Ouest, Saint-Herblain, ARPEGO Network, France.
  • Institut Jules Bordet, Brussels, Belgium.
  • IUCT-Oncopole Claudius Régaud, Toulouse, France.
  • Centre Eugène Marquis, Rennes, France.
  • Institut Gustave Roussy, Villejuif, France.
  • OSE Immunotherapeutics, Nantes, France.

Zitieren

APA

Robert, M., Kotecki, N., Gomez-Roca, C., Massard, C., Postel-Vinay, S., Raimbourg, J., Brandao, M., Korakis, I., Rouge, T. M., Comis, S., Imadalou, K., Chevalier, C., Cordonnier, L., Josse, C., Teppaz, G., Seité, M., Durand, J., Thepenier, V., Mary, C., …, & Cassier, P. A. (2026). A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116729

Vancouver

Robert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, et al. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116729

BibTeX
@article{Robert2026,
  author = {Robert, Marie and Kotecki, Nuria and Gomez-Roca, Carlos and Massard, Christophe and Postel-Vinay, Sophie and Raimbourg, Judith and Brandao, Mariana and Korakis, Iphigénie and Rouge, Thibaut de la Motte and Comis, Silvia and Imadalou, Karima and Chevalier, Caroline and Cordonnier, Laurie and Josse, Constant and Teppaz, Géraldine and Seité, Margaux and Durand, Justine and Thepenier, Virginie and Mary, Caroline and Gauttier, Vanessa and Derame, Mylène and Morello, Aurore and Poirier, Nicolas and Cassier, Philippe Alexandre},
  title = {A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116729}
}
Kostenlos starten →